drugset
drugset / Trial / NCT04563507

Combined Immunotherapies in Metastatic ER+ Breast Cancer

NCT04563507 ↗

Phase 2 Recruiting 102 enrolled Weill Medical College of Cornell University
RandomizedParallel-groupOpen-labelTreatment

Summary

Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to also receive Stereotactic Body Radiation Therapy(SBRT) to each metastatic lesion.

Timeline

Start
2020-11-12
Primary completion
2027-10-31
Completion
2028-10-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Letrozole Other / unclassified 2.5 mg Oral
Comparator Palbociclib Small molecule 125 mg —

Indications

breast cancer